ROLE OF ORAL ZINC IN CHILDREN WITH NEPHROTIC SYNDROME
Not Applicable
- Conditions
- Health Condition 1: N049- Nephrotic syndrome with unspecified morphologic changes
- Registration Number
- CTRI/2021/01/030586
- Lead Sponsor
- REDDY NIKHIL RAJESHWAR
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All children between 1 to 12 years of age with diagnosis of steriod sensitive nephrotic syndrome
Exclusion Criteria
secondary Nephrotic syndrome
congenital nephrotic syndrome
steriod resistant nephrotic syndrome
nephritic syndrome
patient who have taken zinc theraphy in last 3 months
age < 1year and > 12year
chronic infection (TB)
severe Iron deficiency anemia
patients whose parent didnt give consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Role of zinc supplementation in reduction of relapses in study group as compared to placebo groupTimepoint: June 2022
- Secondary Outcome Measures
Name Time Method Role of zinc in reduction of infection rate , mean growth,cumulative dose of steroid and adverse effects in children with steroid sensitive nephrotic syndromeTimepoint: patients will be evaluated for number of relapses at 1 month, 2 months, 4 months and 6 months of study
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie zinc supplementation's efficacy in steroid-sensitive nephrotic syndrome (SSNS) pediatric patients?
How does oral zinc supplementation compare to standard-of-care in reducing proteinuria recurrence in SSNS children?
Which biomarkers correlate with improved outcomes in CTRI/2021/01/030586 zinc adjunct therapy for SSNS?
What adverse effects are associated with zinc supplementation in pediatric nephrotic syndrome and how are they managed?
Are there synergistic effects of combining zinc with immunosuppressants like cyclosporine in SSNS treatment pathways?